Topical fixed-dose combinations: Current in vitro methodologies for pre-clinical development.

Area of Science:

• Pharmaceutical Sciences
• Dermatology
• Pharmacology

Background:

• Fixed-dose combination (FDC) products for topical administration combine multiple active pharmaceutical ingredients (APIs) in a single dosage form.
• These FDCs are a promising strategy for treating various conditions, notably pain and inflammation.
• Pre-clinical development focuses on API interactions and ensuring safety and efficacy of the final product.

Purpose of the Study:

• To review regulatory-accepted in vitro safety tests for topical products.
• To outline common scientific literature methods for assessing anti-inflammatory activity.
• To propose a novel approach for selecting FDC products with enhanced therapeutic potential.

Main Methods:

• Review of regulatory guidelines for in vitro safety assessments of cutaneous products.
• Compilation of established in vivo and in vitro models for evaluating anti-inflammatory effects.
• Development of a quantitative index integrating multiple target effects for FDC selection.

Main Results:

• Identified key in vitro tests for topical product safety evaluation.
• Summarized prevalent methods for assessing anti-inflammatory activity in pre-clinical settings.
• Proposed a rationalized approach for selecting FDCs based on a composite index.

Conclusions:

• Standardized in vitro safety testing is crucial for topical FDCs.
• Existing models for anti-inflammatory assessment require careful application.
• The proposed index offers a systematic method to optimize FDC selection for improved pain and inflammation management.